Sorafenib in patients with progressive epithelioid hemangioendothelioma. Issue 14 (15th April 2013)

• Record Type: Journal Article
• Authors: Chevreau, Christine; Le Cesne, Axel; Ray‐Coquard, Isabelle; Italiano, Antoine; Cioffi, Angela; Isambert, Nicolas; Robin, Yves Marie; Fournier, Charles; Clisant, Stéphanie; Chaigneau, Loic; Bay, Jacques‐Olivier; Bompas, Emmanuelle; Gauthier, Eric; Blay, Jean Y.; Penel, Nicolas
• Is Part Of: Cancer. Volume 119:Issue 14(2013)
• Page Start: 2639
• Page End: 2644
• Publication Date: 2013-04-15
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28109
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28109-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored.</p> </sec> <sec id="cncr28109-sec-0002" sec-type="section"> <title>METHODS</title> <p>In this multicenter, 1‐stage, phase 2 trial of sorafenib (800 mg daily), the primary endpoint, which was chosen by default, was the 9‐month progression‐free rate. All patients had documented progressive disease at the time of study entry.</p> </sec> <sec id="cncr28109-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Fifteen patients were enrolled between June 2009 and February 2011. The median age was 57 years (range, 31‐76 years), and the ratio of men to women was 9:6. The performance status was zero in 10 patients and 1 in 5 patients. Twelve patients had metastases, mainly in the lung (12 patients), liver (5 patients), and bone (3 patients). Five patients had received prior chemotherapy (doxorubicin in 5 patients and taxane in 3 patients). The median sorafenib treatment duration was 124 days (range, from 27 to >271 days). Seven patients required dose reductions or transient treatment discontinuation. The 9‐month progression‐free rate was 30.7% (4 of 13 patients). The 2‐month, 4‐month, and 6‐month progression‐free rate was 84.6% (11 of 13 patients), 46.4% (6 of 13 patients), and 38.4% (5 of 13 patients), respectively. Two partial responses were observed that lasted 2 months and 9 months.</p> </sec> <sec id="cncr28109-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Further clinical trials exploring sorafenib as treatment of progressive EHE are needed. <bold><italic>Cancer</italic> 2013;119:2639–2644</bold>. © <italic>2013 American Cancer Society</italic>.</p> </sec> </abstract>